Crossmark

Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study

Published Online: 2019-12-30

Published Print: 2019-12

Authors

Glaser, Rebecca L. https://orcid.org/0000-0001-5747-3448
York, Anne E.

Dimitrakakis, Constantine
License Information

Text and Data Mining valid from 2019-12-01

Version of Record valid from 2019-12-30
More Information

Article History

Received: 12 September 2019

Accepted: 11 December 2019

First Online: 30 December 2019

Ethics approval and consent to participate

: Informed written consent was obtained from all participants. The prospective study (Testosterone Implants and incidence of breast cancer-TIBcaP 0108) was approved March of 2008 by the Atrium Medical Center’s Institutional Review Board, One Medical Center Dr., Middletown, Ohio. In 2018 the Casey Research Foundation IRB board approved a retrospective chart review ‘Testosterone implants and the Incidence of Breast Cancer (TIBCaP)’, registered with(NCT03768128).

: not applicable.

: CD none declared. AY none declared. RG has a patent issued: Pharmaceutical compositions containing testosterone and an aromatase inhibitor. No financial or other COI declared.

Document is current